Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

AGM Statement

11 Jun 2014 07:00

RNS Number : 3118J
Sopheon PLC
11 June 2014
 



SOPHEON PLC

 

AGM Statement

 

At the Annual General Meeting of Sopheon plc to be held later today, the chairman of the board will give shareholders an update and review of the business. This will include the following statement:

 

"After a very solid performance in 2012, we were pleased to report another year of growth in 2013 with revenues rising to £13.3m. Profitability continued to improve as well, with EBITDA at £1.9m and profit before tax £341,000. Our focus on vertical markets resulted in several new license wins with consumer goods companies. Our work with major consulting partners also continued to gather pace. Sopheon's agile development methodology resulted in two milestone software releases with Accolade 8.3 and 9.0. Furthermore, a number of corporate milestones were progressed in 2013; we secured court approval for a capital reduction, reducing the deficit on the Group's accumulated reserves and we implemented a share consolidation which reduced the number of shares in issue by a ratio of 20:1 and decreased the number of very small shareholdings by over 5,000.

 

As we first predicted some years ago, we believe the market in which Sopheon operates is shifting to one that is more operationally critical, with higher exposure to senior management, just as ERP and CRM shifted in earlier times. Interactions with customers such as PepsiCo, BASF, SABIC and Philips, and coverage from analysts such as Gartner, demonstrate rising acknowledgement that innovation is becoming an enterprise level priority, which requires enterprise level software. We are also seeing and participating in the first conferences aimed directly at Chief Innovation Officers. This changing environment can lead to more phased multi-year client relationships with elongated revenue profiles - but with greater and more strategic long term potential. Since the start of the year we have brought new blood into our US sales team in part to reflect these trends in the market. We are particularly pleased to announce Sheila Plunkett as the US vice president of sales. Sheila joined us in April and has extensive experience gained from both large companies such as IBM, E&Y and SAP as well as small start-up software companies, building a record of developing enterprise sales teams that deliver results.

 

At this time last year, we noted that we were working to close a considerable amount of license business, some of which was needed in June to enable first half revenues to exceed those in the equivalent period in 2012. Last year, we managed to achieve that goal. Revenue visibility today again stands above £8m, comparable to a year ago; and there are again plenty of deals we are striving to close by the end of June. However, looking at the current sales pipeline, and the recognition profile of closed business, we expect that revenues in 2014 will be heavily weighted to the second half of the year. As we have always emphasised, the actual timing and value of individual sales events can have a substantial impact on reported performance for a given period, as can the market developments and sales team changes mentioned above.

 

Looking beyond sales and operations, the high pitch of product release has continued during the last six months, with the release of Accolade® 9.1 in April, advancing our enterprise portfolio and planning capabilities. We have continued to work on our corporate restructuring program, negotiating $3.5m in new debt facilities with Silicon Valley Bank, at lower interest cost, and more recently we have secured agreement to extend the maturity of our convertible loan note by an additional two years. However, as noted before, incorrect processing of our share consolidation by certain Netherlands market participants means that the board is planning to repeat the procedure, and our current plan is to do this after publication of our interim results. Also unfortunate was Euronext's decision to wind down the Alternext Amsterdam segment, relatively soon after we were encouraged to join it. Options available to Sopheon include a transfer of our listing back to the Euronext Amsterdam main market, a transfer to Alternext Paris or Brussels, or a consolidation solely onto our primary AIM listing in London. We will continue to explore all alternatives and will inform shareholders accordingly."

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM at the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMLLFERRIIILIS
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.